IDEAYA Biosciences
IDYA
36.26
-0.37
-1.01%
IDEAYA Biosciences
US · IDYA
#2357 by market cap
Listed 2019
36.26
-0.37
-1.01%
Live - 5344 symbols - heartbeat 468s ago
· 2026-10-08 07:51
Pre-market
36.25
-0.03%
After-hours
36.26
0.00%
- Market cap
- 3.50B
- P/E (TTM)i
- -18.89
- P/Bi
- 2.92
- EPSi
- -1.28
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on IDYA?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 10 analysts
Buy
Avg price target
54.44 +50.1%
Price target rangecurrent 36.26
Low42.00
Avg54.44
High65.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-27 | LifeSci Capital | -- | BUY | 58.00 |
| 2026-09-18 | LifeSci Capital | -- | BUY | 58.00 |
| 2026-09-10 | Citi | -- | BUY | 65.00 |
| 2026-09-09 | LifeSci Capital | -- | BUY | 58.00 |
| 2026-09-09 | Guggenheim | -- | BUY | 57.00 |
| 2026-09-01 | Mizuho Securities | -- | BUY | 50.00 |
| 2026-09-01 | Truist Financial | -- | BUY | -- |
| 2026-08-31 | LifeSci Capital | -- | BUY | 58.00 |
| 2026-08-20 | Mizuho Securities | -- | BUY | 50.00 |
| 2026-08-20 | Wedbush | -- | BUY | 60.00 |
| 2026-08-19 | LifeSci Capital | -- | BUY | 58.00 |
| 2026-08-10 | J.P. Morgan | -- | BUY | 62.00 |
| 2026-08-08 | LifeSci Capital | -- | BUY | 58.00 |
| 2026-08-07 | Mizuho Securities | -- | BUY | 50.00 |
| 2026-08-06 | Citizens JMP | -- | BUY | 42.00 |
| 2026-08-05 | Wells Fargo | -- | BUY | 48.00 |
| 2026-08-05 | Truist Financial | -- | BUY | 59.00 |
| 2026-08-05 | Wedbush | -- | BUY | 60.00 |
| 2026-08-04 | LifeSci Capital | -- | BUY | 58.00 |
| 2026-08-04 | Guggenheim | -- | BUY | 54.00 |
| 2026-08-04 | RBC Capital | -- | BUY | 48.00 |
| 2026-08-01 | LifeSci Capital | -- | BUY | 62.00 |
| 2026-07-29 | Mizuho Securities | -- | BUY | 50.00 |
| 2026-07-27 | LifeSci Capital | -- | BUY | 62.00 |
| 2026-07-07 | Truist Financial | -- | BUY | 63.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Buy
Analyst consensus
Buy
All 3 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 07:51:59 · For reference only, not investment advice and not tailored to your situation.